

concurrently herewith. The Request for Continued Examination is being filed in lieu of the Notice of Appeal. Reconsideration and further examination are respectfully requested.

Please amend the application as follows:

In the Claims

Add new Claims 60-61 as follows.

- 
60. (New) The method of claim 21, wherein in step (a), said body fluid is analyzed to detect presence and concentration level of two or more ischemic marker proteins selected from the group consisting of myelin basic protein (MBP), the beta isoform of S100 protein (S100), and neuronal specific enolase (NSE).
61. (New) The method of claim 40, wherein in step (a), said body fluid is analyzed to detect presence and concentration level of three or more proteins selected from the group consisting of myelin basic protein (MBP), the beta isoform of S100 protein (S100), neuronal specific enolase (NSE) and a brain endothelial cell membrane protein.
- 

REMARKS

New Claims 60-61

Support for new Claims 60-61 can be found throughout the specification, for example, at pages 15 to 27 and FIG. 2. No new matter is added by the addition of these claims.

Amendment After Final Rejection Under 37 C.F.R. 1.116

Applicant respectfully requests entry and consideration of the Amendment After Final Rejection Under 37 C.F.R. 1.116, filed March 18, 2002.

Advisory Action Mailed April 1, 2002 (Paper No. 17)

The Advisory Action indicates that the proposed amendments in the Amendment After Final Rejection Under 37 C.F.R. 1.116, filed March 18, 2002, (1) "raise new issues that would require further consideration and/or search"; (2) "raise the issue of new matter"; (3) "are not deemed to place the application in better form for appeal by materially reducing or simplifying